MDL | MFCD00814248 |
---|---|
Molecular Weight | 361.61 |
Molecular Formula | C14H11Cl3N2O3 |
SMILES | O=C(C(N1CCOCC1)=C2Cl)N(C3=CC=C(Cl)C(Cl)=C3)C2=O |
RI-1 is a RAD51 inhibitor, with IC 50 s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells [1] .
IC50: 5-30 μM (RAD51) [1]
RI-1 (1-50 µM; 24 h) specifically inhibits homologous recombination (HR) in U2OS cells and stimulates single-strand annealing (SSA) in HEK293 cells
[1]
.
RI-1 (5-20 µM; 30 min) inhibits HsRAD51 in a concentration-dependent manner
[1]
.
RI-1 (20 µM; 8 h) disrupts the formation of RAD51 foci after DNA damage in immortalized human fibroblasts
[1]
.
RI-1 (15-25 µM; 24 h) sensitizes human cancer cells (HeLa, MCF-7 and U2OS) to cross-linking chemotherapy
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
RI-1 (50 mg/kg; i.p. every 3 d for 30 d) significantly reduces triple negative breast cancer (TNBC) tumor growth in mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Female BALB/c nude mice (6 weeks) bearing TNBC tumor [2] |
Dosage: | 50 mg/kg |
Administration: | I.p. every 3 days for 30 days |
Result: |
Resulted in significant inhibition of tumor growth.
Did not cause body weight loss significantly. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 33.33 mg/mL ( 92.17 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.7654 mL | 13.8271 mL | 27.6541 mL |
5 mM | 0.5531 mL | 2.7654 mL | 5.5308 mL |
10 mM | 0.2765 mL | 1.3827 mL | 2.7654 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.91 mM); Clear solution